Last $26.96 USD
Change Today -0.24 / -0.88%
Volume 62.6K
AEGR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 9:55 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

aegerion pharmaceuticals inc (AEGR) Snapshot

Open
$27.19
Previous Close
$27.20
Day High
$27.58
Day Low
$26.86
52 Week High
03/7/14 - $58.08
52 Week Low
10/31/14 - $19.10
Market Cap
766.6M
Average Volume 10 Days
580.6K
EPS TTM
$-1.36
Shares Outstanding
28.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AEGERION PHARMACEUTICALS INC (AEGR)

aegerion pharmaceuticals inc (AEGR) Related Businessweek News

No Related Businessweek News Found

aegerion pharmaceuticals inc (AEGR) Details

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products include JUXTAPID (lomitapide) and LOJUXTA (lomitapide) hard capsules, the adjuncts to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia; and MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It also has the right to use lomitapide in the field of monotherapy or in combination with other dyslipidemic therapies for treatment of patients with other severe forms of hypercholesterolemia. The company distributes its products directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

aegerion pharmaceuticals inc (AEGR) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $584.2K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $350.0K
Chief Operating Officer
Total Annual Compensation: $340.0K
Chief Medical Officer
Total Annual Compensation: $380.0K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2013.

aegerion pharmaceuticals inc (AEGR) Key Developments

Aegerion Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reiterates Earnings Guidance for the Year 2015; Provides Cash Flow Guidance for the First Quarter of 2015

Aegerion Pharmaceuticals, Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net product sales of $51,712,000 compared to $24,495,000 a year ago. Income from operations was $75,000 compared with loss from operations of $13,538,000 for the same period a year ago. Net loss before provision for income taxes was $7,744,000 compared with $13,669,000 for the same period a year ago. Net loss was $8,116,000 or $0.29 per basic and diluted share compared with $13,852,000 or $0.47 per basic and diluted share for the same period a year ago. Non-GAAP net income was $2,999,000 or $0.11 per basic share compared with non- GAAP net loss of $3,936,000 or $0.13 per basic share for the same period a year ago. The company achieved positive cash flow from operations of approximately $9.2 million during the fourth quarter, bringing second half 2014 total positive cash flow from operations to $17.9 million. For the quarter, the company reported net product sales of $158,373,000 compared to $48,546,000 a year ago. Loss from operations was $26,702,000 compared with $62,347,000 for the same period a year ago. Net loss before provision for income taxes was $38,486,000 compared with $63,011,000 for the same period a year ago. Net loss was $39,385,000 or $1.35 per basic and diluted share compared with $63,358,000 or $2.19 per basic and diluted share for the same period a year ago. Non-GAAP net loss was $2,383,000 or $0.08 per basic share compared with $35,609,000 or $1.23 per basic share for the same period a year ago. The company reiterated earnings guidance for the year 2015. Aegerion expects full-year 2015 global net product sales of JUXTAPID to be between $195 million and $215 million. Aegerion expects full-year 2015 global net product sales of MYALEPT to be between $10 million and $20 million. Aegerion expects full-year 2015 total non-GAAP operating expenses of between $195 million and $205 million. Aegerion expects to generate positive cash flow from operations for the full-year of 2015. The company expects full year total net product sales to be between $205 million and $235 million in 2015 The company expects negative cash flow in the first quarter of 2015 as transition MYALEPT to related obligations and operations into its year end.

Aegerion Pharmaceuticals, Inc. to Report Q4, 2014 Results on Feb 26, 2015

Aegerion Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 8:05 PM, GMT Standard Time on Feb 26, 2015

Aegerion Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 26, 2015

Aegerion Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $26.96 USD -0.24

AEGR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEGR.
View Industry Companies
 

Industry Analysis

AEGR

Industry Average

Valuation AEGR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit www.aegerion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.